Skip to main content
Apellis Pharmaceuticals, Inc. logo

Apellis Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · APLS ISIN · US03753U1060 LEI · 254900HS0ZFRXXSB9D42 US Manufacturing
Open in API
Filings indexed 1,129 across all filing types
Latest filing 2020-01-07 Capital/Financing Update
Country US United States of America
Listing US APLS

About Apellis Pharmaceuticals, Inc.

https://apellis.com/

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing therapies for a broad range of debilitating diseases by targeting the complement cascade. The company's scientific approach is centered on controlling C3, a central protein in this part of the immune system, to treat conditions driven by its overactivation. Apellis's development efforts are concentrated in the areas of ophthalmology, hematology, and nephrology. Its portfolio of approved medicines includes SYFOVRE® (pegcetacoplan injection) for the treatment of geographic atrophy (GA) and EMPAVELI® (pegcetacoplan) for other serious, complement-driven diseases.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) related to a common stock offering by Apellis Pharmaceuticals, Inc. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and company overview. The document is clearly a registration and offering prospectus supplement for a capital raise, describing the terms of the stock offering and related financial and business information. It is not a financial report, earnings release, management discussion, or any other type of report. The presence of Rule 424(b)(5) and the nature of the content indicate this is a Capital/Financing Update filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-01-07 English
S-3ASR
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC by Apellis Pharmaceuticals, Inc. It is a registration statement under the Securities Act of 1933 for the offering of securities such as debt securities, common stock, preferred stock, units, and warrants. The document includes a prospectus describing the general terms of the securities to be offered and the manner of offering. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement of a report.
2020-01-07 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content focuses on announcing top-line data from a Phase 3 clinical trial (PEGASUS trial) for a drug, including efficacy and safety results, and plans to meet with regulatory agencies. There are no comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). It is not a transcript, proxy, or governance document. The document is a standalone announcement of clinical trial results and other material events, fitting the category of a Regulatory Filing (RNS) as it does not fit other specific categories and is a general regulatory announcement. The document length (9137 characters) and detailed content confirm it is not a brief announcement or a report publication announcement (RPA). Therefore, the best classification is Regulatory Filings (RNS).
2020-01-07 English
PRIMARY DOCUMENT
Director's Dealing
2020-01-03 English
PRIMARY DOCUMENT
Director's Dealing
2020-01-03 English
PRIMARY DOCUMENT
Director's Dealing
2020-01-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.